Sinopharm Group Co ( (HK:1099) ) has provided an update.
Sinopharm Group Co. Ltd. announced the principal unaudited financial data for its subsidiary, China National Medical Device Co., Ltd. (CNMDC), for the first quarter of 2025. The report highlights a slight decline in revenue by 0.94% and a 7.39% drop in operating profit compared to the same period last year. However, total comprehensive income attributable to the parent company’s owners increased by 5.79%. Notably, net cash flow from operating activities improved significantly, showing a 56.34% decrease in negative cash flow. These financial results indicate a stable asset growth with total assets increasing by 2.83% and total equity rising by 1.58%, reflecting a cautious yet positive outlook for the company’s financial health.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. operates in the healthcare industry, focusing on the distribution and provision of medical devices and pharmaceuticals. As a major player in the Chinese market, the company has a significant presence through its subsidiary, China National Medical Device Co., Ltd. (CNMDC), which specializes in medical devices.
YTD Price Performance: -19.78%
Average Trading Volume: 2,115
Technical Sentiment Signal: Buy
Current Market Cap: $7.23B
Learn more about 1099 stock on TipRanks’ Stock Analysis page.